A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies

BACKGROUND: To determine the prevalence of RET rearrangement genes, RET copy number gains and expression in tumor samples from four Phase III non-small-cell lung cancer (NSCLC) trials of vandetanib, a selective inhibitor of VEGFR, RET and EGFR signaling, and to determine any association with outcome...

Descripción completa

Detalles Bibliográficos
Autores principales: Platt, Adam, Morten, John, Ji, Qunsheng, Elvin, Paul, Womack, Chris, Su, Xinying, Donald, Emma, Gray, Neil, Read, Jessica, Bigley, Graham, Blockley, Laura, Cresswell, Carl, Dale, Angela, Davies, Amanda, Zhang, Tianwei, Fan, Shuqiong, Fu, Haihua, Gladwin, Amanda, Harrod, Grace, Stevens, James, Williams, Victoria, Ye, Qingqing, Zheng, Li, de Boer, Richard, Herbst, Roy S, Lee, Jin-Soo, Vasselli, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412099/
https://www.ncbi.nlm.nih.gov/pubmed/25881079
http://dx.doi.org/10.1186/s12885-015-1146-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412099/
https://www.ncbi.nlm.nih.gov/pubmed/25881079
http://dx.doi.org/10.1186/s12885-015-1146-8

Ejemplares similares